24/7 Market News Snapshot 11 June, 2025 – Helius Medical Technologies, Inc. Class A Common Stock (DE) (NASDAQ:HSDT)

June 11, 2025

DENVER, Colo., 11 June, 2025 (www.247marketnews.com) – (Nasdaq:HSDT) are discussed in this article.
Helius Medical Technologies, Inc. (Nasdaq:HSDT), a leader in neurotechnology aimed at addressing balance and gait deficits, has seen a significant spike in its stock, which climbed to $1.496 in pre-market trading—an impressive increase of 77.04% from the previous close of $0.845. This surge is corroborated by a substantial trading volume of 7.69 million shares, reflecting strong investor interest and confidence in the company’s future prospects.

In a pivotal development for patient access to innovative treatments, Helius announced that Aetna Healthcare has authorized reimbursement claims for its Portable Neuromodulation Stimulator (PoNS) Device. This major advancement marks the third substantial endorsement from a healthcare provider, following similar agreements with Anthem and United. The PoNS Device, designed for individuals with multiple sclerosis (MS), represents a breakthrough in treatment by integrating non-implantable neurostimulation with an associated physical rehabilitation program to enhance balance and gait.

The negotiated out-of-network price for the PoNS therapy is set at $18,350, a crucial factor in expanding access for patients who would benefit from this revolutionary treatment. Dane Andreeff, President and CEO of Helius, emphasized the importance of this achievement, stating, “We are thrilled about Aetna’s recent decision to provide reimbursement for the PoNS Device, which underscores the growing acknowledgment of our innovative technology in the healthcare community.” Helius remains committed to broadening its reimbursement landscape further, striving to support patients reliant on Medicare and to align commercial payments with existing healthcare programs.

Indicated for adults aged 22 and above experiencing mild to moderate MS symptoms, the PoNS Device is intended as a short-term therapeutic adjunct to exercise programs targeting gait deficits. Helius Medical Technologies continues its mission to improve the lives of those suffering from neurologic conditions through targeted and evidence-based therapies.

Related news for (HSDT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.